NO20030213L - Anvendelse av D2/D3 reseptor-agonister for behandling av fibr omyalgi - Google Patents

Anvendelse av D2/D3 reseptor-agonister for behandling av fibr omyalgi

Info

Publication number
NO20030213L
NO20030213L NO20030213A NO20030213A NO20030213L NO 20030213 L NO20030213 L NO 20030213L NO 20030213 A NO20030213 A NO 20030213A NO 20030213 A NO20030213 A NO 20030213A NO 20030213 L NO20030213 L NO 20030213L
Authority
NO
Norway
Prior art keywords
fibromyalgia
treatment
receptor agonists
agonists
receptor
Prior art date
Application number
NO20030213A
Other languages
English (en)
Norwegian (no)
Other versions
NO20030213D0 (no
Inventor
Andrew J Holman
Original Assignee
Andrew J Holman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andrew J Holman filed Critical Andrew J Holman
Publication of NO20030213D0 publication Critical patent/NO20030213D0/no
Publication of NO20030213L publication Critical patent/NO20030213L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20030213A 2000-07-17 2003-01-16 Anvendelse av D2/D3 reseptor-agonister for behandling av fibr omyalgi NO20030213L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/617,177 US6277875B1 (en) 2000-07-17 2000-07-17 Use of dopamine D2/D3 receptor agonists to treat fibromyalgia
PCT/US2001/021530 WO2002005797A2 (fr) 2000-07-17 2001-07-05 Utilisation d'agonistes du recepteur d2/d3 de la dopamine destine au traitement de la fibromyalgie

Publications (2)

Publication Number Publication Date
NO20030213D0 NO20030213D0 (no) 2003-01-16
NO20030213L true NO20030213L (no) 2003-03-11

Family

ID=24472575

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030213A NO20030213L (no) 2000-07-17 2003-01-16 Anvendelse av D2/D3 reseptor-agonister for behandling av fibr omyalgi

Country Status (17)

Country Link
US (2) US6277875B1 (fr)
EP (1) EP1311251A2 (fr)
JP (1) JP2004503587A (fr)
KR (1) KR100797603B1 (fr)
CN (1) CN1443066A (fr)
AU (2) AU2001271910B2 (fr)
BR (1) BR0112476A (fr)
CA (1) CA2414774C (fr)
CZ (1) CZ2003417A3 (fr)
HU (1) HUP0301305A3 (fr)
IL (1) IL153915A0 (fr)
MX (1) MXPA03000336A (fr)
NO (1) NO20030213L (fr)
NZ (1) NZ523926A (fr)
PL (1) PL360121A1 (fr)
WO (1) WO2002005797A2 (fr)
ZA (1) ZA200300588B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2404704A1 (fr) * 2000-04-21 2001-11-22 David W. Robertson Traitement de la cellulomyalgie et du syndrome de fatigue chronique
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
US20020165246A1 (en) * 2001-03-05 2002-11-07 Andrew Holman Administration of sleep restorative agents
DE10137162A1 (de) * 2001-07-30 2003-02-20 Hexal Ag Matrixkontrolliertes transdermales therapeutisches System zur Anwendung von Pramiprexol und Ropinirol
DE10138275A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Verbindungen zur Beseitigung der Anhedonie
GB0125088D0 (en) * 2001-10-18 2001-12-12 Smithkline Beecham Cork Ltd New use
US7079888B2 (en) * 2002-04-11 2006-07-18 Ansar, Inc. Method and apparatus for monitoring the autonomic nervous system using non-stationary spectral analysis of heart rate and respiratory activity
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
MY136318A (en) * 2002-07-25 2008-09-30 Pharmacia Corp Sustained-release tablet composition
US20050226926A1 (en) * 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
AR040682A1 (es) * 2002-07-25 2005-04-13 Pharmacia Corp Forma de dosificacion una vez al dia de pramipexol
US20040092504A1 (en) * 2002-11-12 2004-05-13 Anuthep Benja-Athon Definitive medications for treating fibromyalgia
EP1426049B1 (fr) * 2002-12-02 2005-05-18 Schwarz Pharma Ag Administration par iontophorèse de rotigotine pour traiter la maladie de Parkinson
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
EA200900930A1 (ru) * 2004-08-13 2009-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Композиция таблетки с пролонгированным высвобождением, содержащая прамипексол или его фармацевтически приемлемую соль, способ ее изготовления и ее применение
CN101849920A (zh) * 2004-08-13 2010-10-06 贝林格尔·英格海姆国际有限公司 包含普拉克索或其可药用盐的延长释放小球制剂、其制备方法及其用途
WO2007048034A2 (fr) * 2005-10-21 2007-04-26 Caritas St. Elizabeth Medical Center Of Boston, Inc. Utilisation d'androgenes dans le traitement de la maladie de parkinson
US20090098202A1 (en) * 2006-02-10 2009-04-16 Boehringer Ingelheim International Gmbh Extended Release Formulation
WO2007090881A2 (fr) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Formulation a liberation modifiee
TWI392670B (zh) * 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
CN1944647B (zh) * 2006-08-23 2010-05-12 华东师范大学 多巴胺受体新亚型d5b基因及编码的蛋白与应用
GB0700786D0 (en) * 2007-01-15 2007-02-21 Pfizer Ltd Morpholine dopamine agonists for the treatment of pain
EP1987815A1 (fr) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Compositions pharmaceutiques à base d'agonistes dopaminergiques administrables par voie oro-naso-pharyngale pour la prévention et/ou le traitement de membres sans repos
WO2010023693A2 (fr) * 2008-09-01 2010-03-04 Lupin Limited Nouvelles compositions de ropinirole à libération contrôlée
EP2346494A2 (fr) 2008-09-29 2011-07-27 Wockhardt Limited Forme posologique à libération prolongée de ropinirole
WO2010044108A2 (fr) 2008-10-17 2010-04-22 Rubicon Research Private Limited Formulations à libération contrôlée de ropinirole
WO2011139420A2 (fr) 2010-04-30 2011-11-10 Teikoku Pharma Usa, Inc. Compositions transdermiques de propynylaminoindane
EP2688561B1 (fr) 2011-03-24 2018-08-22 Teikoku Pharma USA, Inc. Compositions transdermiques comprenant une couche d'agent actif et une couche de conversion d'agent actif
WO2013070526A1 (fr) 2011-11-09 2013-05-16 Teikoku Pharma Usa, Inc. Méthodes pour le traitement de tumeurs de la peau
BR112015007872A2 (pt) 2012-11-02 2017-07-04 Teikoku Pharma Usa Inc composições transdermais de propinilaminoindano
MA41125A (fr) 2014-12-05 2017-10-10 Purdue Pharma Lp Dérivés de 6.7-cyclomorphinane et leur utilisation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4414224A (en) * 1980-08-22 1983-11-08 Smithkline Beckman Corporation Pharmaceutical composition and methods for producing dopamine agonist activity
US4879391A (en) * 1982-09-20 1989-11-07 Pfizer Inc. 1-Phenyl-2(1H,3H)-indolone psychotherapeutic agents
US4452808A (en) * 1982-12-07 1984-06-05 Smithkline Beckman Corporation 4-Aminoalkyl-2(3H)-indolones
ATE45735T1 (de) 1984-12-22 1989-09-15 Thomae Gmbh Dr K Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arnzneimittel.
DE3447075A1 (de) * 1984-12-22 1986-07-03 Dr. Karl Thomae Gmbh, 7950 Biberach Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arzneimittel
GB8712073D0 (en) * 1987-05-21 1987-06-24 Smith Kline French Lab Medicament
US5498610A (en) * 1992-11-06 1996-03-12 Pfizer Inc. Neuroprotective indolone and related derivatives
US5696128A (en) 1994-07-07 1997-12-09 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method of regulating immune function
US5658955A (en) 1994-11-01 1997-08-19 Hitzig; Pietr Combined use of dopamine and serotonin agonists in the treatment of immune disorders
CA2404704A1 (fr) * 2000-04-21 2001-11-22 David W. Robertson Traitement de la cellulomyalgie et du syndrome de fatigue chronique

Also Published As

Publication number Publication date
EP1311251A2 (fr) 2003-05-21
NO20030213D0 (no) 2003-01-16
KR20030029625A (ko) 2003-04-14
US6277875B1 (en) 2001-08-21
NZ523926A (en) 2006-05-26
CA2414774C (fr) 2010-09-07
HUP0301305A3 (en) 2008-03-28
ZA200300588B (en) 2004-04-22
WO2002005797A2 (fr) 2002-01-24
MXPA03000336A (es) 2005-04-19
JP2004503587A (ja) 2004-02-05
IL153915A0 (en) 2003-07-31
KR100797603B1 (ko) 2008-01-28
WO2002005797A8 (fr) 2003-03-06
CA2414774A1 (fr) 2002-01-24
BR0112476A (pt) 2003-07-22
PL360121A1 (en) 2004-09-06
CN1443066A (zh) 2003-09-17
US6300365B1 (en) 2001-10-09
HUP0301305A2 (hu) 2003-08-28
AU7191001A (en) 2002-01-30
CZ2003417A3 (cs) 2003-08-13
AU2001271910B2 (en) 2005-07-28

Similar Documents

Publication Publication Date Title
NO20030213L (no) Anvendelse av D2/D3 reseptor-agonister for behandling av fibr omyalgi
DE69939396D1 (de) Verfahren für das ausdehnen des gebrauches des sip protokolls
DE69936767D1 (de) Patientenmonitor
EE200400026A (et) 5-HT retseptori ligandid ja nende kasutamine
DK1112106T3 (da) Serotonerge 5HT2-agonister til behandling af glaukom
DE60104179D1 (de) Chirurgisches Gerät für den Glaskörper
IS5699A (is) Ný notkun
EE200300239A (et) Rosuvastatiini (ZD4522) kasutamine heterosügootseperekondliku hüperkolesteroleemia raviks
ZA200305691B (en) The use of substituted azetidione compounds for the treatment of sitosterolemia
FI20000863A (fi) Uusi hoitomenetelmä
DE60226578D1 (de) Chirurgische greifvorrichtung
HK1068551A1 (en) Substituted benzimidazole compounds and their use for the treatment of cancer
PT1321135E (pt) Composicao para o tigimento de oxidacao das fibras ceratinicas
PT1206436E (pt) Retinoides para o tratamento de enfisema
NO20005386D0 (no) Anvendelse av NMDA-antagonister for behandling av irritabel tarmsyndrom
PT1176991E (pt) Dispositivo ceramico para tratamento de feridas
DE60008489D1 (de) Lösbarer Endanschlag
ID30381A (id) Penggunaan arilalkanoilpiridazina
NO20022142L (no) Anvendelse av dopamin-D3 reseptor agonister for behandling av saltavhengig hypertensjon
NO20012301D0 (no) Ny fremgangsmåte for behandling
SE9801673D0 (sv) New medical use of substituted quinolines
DE60232185D1 (de) System zur verwaltung des herzrhythmus
DE50006327D1 (de) Vorrichtungen zur versorgung autarker gebäude
NO20011189L (no) Innretning for behandling av suspensjoner
NO996166L (no) FremgangsmÕte for behandling av avluter

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application